Drug Discovery

FDA grants orphan drug status to Ractigen’s RAG-18 for DMD and BMD

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) product candidate for the treatment of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

Aarvik announces ADC option exercise by collaboration partner ArriVent

Aarvik Therapeutics has announced that its collaboration partner ArriVent BioPharma opted to exclusively license their joint programme.

FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Bavarian Nordic's chikungunya virus vaccine candidate, CHIKV VLP, granting it priority review status.

US FDA approves Purdue Pharma’s Zurnai auto-injector

The US Food and Drug Administration (FDA) has approved Purdue Pharma’s new drug application for Zurnai, the first nalmefene hydrochloride auto-injector, designed for the emergency treatment of opioid overdose.

Santen and Cloudbreak enter licence agreement for pterygium treatment

Santen Pharmaceutical has entered into a licensing agreement with Cloudbreak Pharma to develop, manufacture, and commercialise CBT-001, a topical pterygium treatment, for certain territories.

Genmab assumes full ownership of acasunlimab

Genmab has assumed the complete ownership of the acasunlimab development programme, including its continued development and potential commercialisation, contingent on approval.

Jade Biosciences secures $80m to develop autoimmune therapies

Biotechnology company Jade Biosciences has announced the successful closure of an $80m financing round aimed at developing transformative therapies for autoimmune diseases.

Pinetree secures $17m to advance TPD development programmes

Pinetree Therapeutics has secured $17m in a Series A funding round to advance its new multispecific targeted protein degraders (TPD) development programmes.

Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies

Belgium-based Confo Therapeutics has secured €60m ($65m) in a Series B financing round to propel its pipeline of G protein-coupled receptor (GPCR)-modulating therapies into clinical development.